In Reply

W Nathaniel Brennen¹, Michael T Schweizer^{2

3}, Hao Wang¹, Trinity J Bivalacqua⁴, Alan W Partin⁴, Su Jin Lim¹, Carolyn Chapman¹, Rehab Abdallah¹, Oren Levy^{5

6

7}, Neil A Bhowmick⁸, Jeffrey M Karp^{5

6

7}, Angelo De Marzo⁹, John T Isaacs¹, Samuel R Denmeade¹

Affiliations

¹ Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
² Department of Medicine, University of Washington, Seattle, Washington, USA.
³ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
⁴ Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁵ Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
⁶ Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
⁷ Division of Health Sciences and Technology, Harvard-MIT, Cambridge, Massachusetts, USA.
⁸ Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
⁹ Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Comment

W Nathaniel Brennen et al. Stem Cells Transl Med. 2019 Jul.

. 2019 Jul;8(7):739-740.

doi: 10.1002/sctm.19-0068. Epub 2019 Mar 29.

¹ Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
² Department of Medicine, University of Washington, Seattle, Washington, USA.
³ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
⁴ Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁵ Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
⁶ Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
⁷ Division of Health Sciences and Technology, Harvard-MIT, Cambridge, Massachusetts, USA.
⁸ Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
⁹ Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

No abstract available

Conflict of interest statement

The authors indicated no potential conflicts of interest.

Use of Bone Marrow-Derived Mesenchymal Stem Cells in Prostate Cancer Could Increase the Risk of Cancer Progression.
Raj AT, Kheur S, Bhonde R, Gupta AA, Patil VR, Kharat A. Raj AT, et al. Stem Cells Transl Med. 2019 Jul;8(7):737-738. doi: 10.1002/sctm.19-0050. Epub 2019 Mar 29. Stem Cells Transl Med. 2019. PMID: 30925021 Free PMC article. No abstract available.

1. Raj AJ, Kheur S, Bhonde R et al. Use of Bone Marrow‐Derived Mesenchymal Stem Cells in Prostate Cancer Could Increase the Risk of Cancer Progression. Stem Cells Translational Medicine 2019;8:737–738. - PMC - PubMed
1. Schweizer MT, Wang H, Bivalacqua TJ et al. A phase I study to assess the safety and cancer‐homing ability of allogeneic bone marrow‐derived mesenchymal stem cells in men with localized prostate cancer. Stem Cells Translational Medicine 2019;8:441–449. - PMC - PubMed
1. Klopp AH, Gupta A, Spaeth E et al. Concise review: Dissecting a discrepancy in the literature: Do mesenchymal stem cells support or suppress tumor growth? Stem Cells 2011;29:11–19. - PMC - PubMed
1. Bergfeld SA, DeClerck YA. Bone marrow‐derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev 2010;29:249–261. - PubMed
1. Brennen WN, Nguyen H, Dalrymple SL et al. Assessing angiogenic responses induced by primary human prostate stromal cells in a three‐dimensional fibrin matrix assay. Oncotarget 2016;7:71298–71308. - PMC - PubMed